About 30 results found for searched term "ML-SI3" (0.133 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M20832 | ML-SI3 | TRP Channel |
| ML-SI3 is a potent TRPML channel inhibitor with IC50s of 4.7 µM and 1.7 µM for TRPML1 and TRPML2, respectively. | ||
| M1828 | Tandutinib | FLT3 |
| MLN518, CT53518 | ||
| Tandutinib (MLN518), previously known as CT53518, is an orally active multitargeted tyrosine kinase inhibitor of FLT3, PDGFR and c-Kit. | ||
| M2122 | MLN9708 | Proteasome |
| ixazomib citrate | ||
| MLN9708 is a novel orally bioactive proteasome inhibitor, inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 value of 3.4 nM. | ||
| M2285 | MLN2238 | Proteasome |
| Ixazomib | ||
| MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. | ||
| M5047 | ML216 | Others |
| CID-49852229 | ||
| ML216 is a potent inhibitor of the DNA unwinding activity of BLM helicase; showing similar IC50s of 3.0 and 0.97 μM for full length BLM and BLM636–1298 respectively. | ||
| M7177 | Quinine hydrochloride | Potassium Channel |
| Quinine hydrochloride is the hydrochloride form of Quinine, an alkaloid extracted from the bark of the cinchona tree, with antimalarial and antitumor activities, and an IC50 value of 60 ng/mL against P. falciparum strains passou and 107.8 ng/mL against P. falciparum strain 3CD7, respectively, and an inhibitor of potassium channels. Quinine hydrochloride is also a potassium channel inhibitor that inhibits voltage pulse-induced MT mSlo3 (KCa5.1) channel +100 mV currents, with an IC50 value of 169 μM. In addition, Quinine hydrochloride binds to purine nucleoside phosphorylase (PfNP) and PfNP with low nanomolar affinity. nucleoside phosphorylase (PfPNP) with low nanomolar affinity. | ||
| M7690 | ML-9 | Autophagy |
| ML-9 is a potent, selective Akt kinase inhibitor that inhibits myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. It acts on MLCK, PKA and PKC with Ki values of 4, 32 and 54 μM, respectively. In addition, ML-9 induces autophagy by stimulating the formation of autophagosomes and inhibiting their degradation. | ||
| M8912 | ML-18 | Bombesin Receptor |
| ML18 is Bombesin receptor subtype 3 (BRS-3) antagonist (IC50 = 4.8 μM). | ||
| M10782 | APG-1387 | IAP |
| APG-1387 is a divalent SMAC mimetic that is an IAP antagonist that blocks the activity of the IAP family of proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). APG-1387 induces degradation of cIAP-1 and XIAP proteins as well as caspase-3 activation and PARP lysis, leading to apoptosis. APG-1387 can be used for the study of hepatocellular carcinoma, ovarian cancer and nasopharyngeal carcinoma. | ||
| M11489 | Recombinant Human MCP-1/CCL2 (E. coli) | Recombinant Proteins |
| MCAF; JE; Monocyte Chemotactic Protein-1; CCL2; MCP1 | ||
| The EC50 value of human MCP-1/CCL2 on Ca2+ mobilization assay in CHO-K1/Gα15/hCCR2 cells (human Gα15 and human CCR2 stably expressed in CHO-K1 cells) is less than 1.0 μg/ml. Accession # : P13500. | ||
| M11492 | Recombinant Human Endostatin (P. pastoris) | Recombinant Proteins |
| Endostatin | ||
| Recombinant human Endostatin protein (P. pastoris) is determined by the formation of endothelial cells. Endostatin concentration of 10 μg/ mL showed obvious anti-angiogenesis effect. Protein structure: Endostatin (ALA1571-Lys1754), Accession # P39060. | ||
| M11493 | Recombinant Human SCF (P. pastoris) | Recombinant Proteins |
| Kit ligand; C-Kit Ligand; Mast Cell Growth Factor | ||
| The recombinant human SCF protein stimulated TF-1 cells dose-dependent, ED50 < 2.0 ng/ mL, and corresponding specific activity was 5 × 10< SUP > 5IU/mg. Protein structure: Coexpressed with n-terminal methionine. Accession # : P21583-1. | ||
| M11495 | Recombinant Human TNF-α (E. coli) | Recombinant Proteins |
| TNF-alpha; Tumor necrosis factor ligand superfamily member 2; TNF-a; Cachectin | ||
| Recombinant human TNF-α protein (E. coli) is a homotrimer with a subunit molecular mass of 17.3 kDa. TNF-a plays a major role in growth regulation, differentiation, inflammation, viral replication, tumorigenesis, and autoimmune diseases; and in viral, bacterial, fungal, and parasitic infections. ED50 < 30.0 pg/ml, measured in a cytotoxicity assay using L-929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D, corresponding to a specific activity of > 3.3 × 107 units/mg. | ||
| M14173 | GW806742X hydrochloride | Necroptosis |
| GW806742X hydrochloride is an ATP mimetic and potent inhibitor of MLKL and necroptosis, slowing down MLKL membrane translocation and binding to the MLKL pseudokinase domain with a Kd value of 9.3 μM. GW806742X hydrochloride has anti-VEGFR2 activity (IC50=2 nM). GW806742X hydrochloride has anti-VEGFR2 activity (IC50=2 nM). | ||
| M21096 | TXA6101 | Others |
| TXA6101 is a filamentous temperature-sensitive mutant Z (FtsZ) protein inhibitor. TXA6101 has an antibacterial activity MIC value of 1 μg/mL against MRSA isolates expressing either G193D or G196S mutant FtsZ, retaining significant activity against the TXA707-resistant FtsZ mutant. It is being developed for use against Gram-negative bacteria. | ||
| M21346 | Recombinant Human Cuteaneous T-cell Attracting Chemokine/CCL27 (E.coli ) | Recombinant Proteins |
| AA Sequence：FLLPPSTACC TQLYRKPLSD KLLRKVIQVE LQEADGDCHL QAFVLHLAQR SICIHPQNPS LSQWFEHQER KLHGTLPKLN FGMLRKMG.Accession: Q9Y4X3. | ||
| M21463 | Recombinant Human HB-EGF (E. coli) | Recombinant Proteins |
| HEGFL; Heparin Binding EGF-like growth factor | ||
| HB-EGF signals through the EGF receptor to stimulate the proliferation of smooth muscle cells, epithelial cells and keratinocytes. ED50 < 0.75 ng/ml, measured in a cell proliferation assay using 3T3 cells. | ||
| M27743 | ML359 | PDI |
| ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo. | ||
| M28181 | ML372 | DNA/RNA Synthesis |
| ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M28295 | Ribocil | Antibiotic |
| Ribocil is a highly selective chemical modulator of bacterial riboflavin riboswitches. Ribocil strongly inhibits GFP expression, achieving a 50% effective concentration (EC50) of 0.3 μM. Target: in vitro: Ribocil is a highly specific bioactive synthetic mimic of FMN, which competes with the natural ligand to inhibit FMN riboswitch-mediated expression of ribB and inhibits bacterial growth. Ribocil-B demonstrates superior microbiological activity as compared to Ribocil-A (minimum inhibitory concentration (MIC) = 1 μg/ml versus MIC ≥ 64 μg/ml), inhibition of riboflavin synthesis (IC50 = 0.13 μM versus IC50 > 26 μM), and binding affinity to the E. coli FMN aptamer (Kd = 6.6 nM versus Kd ≥ 10,000 nM).[1] | ||
| M28491 | MRT199665 | Salt-inducible Kinase |
| MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370. | ||
| M28716 | ML380 | AChR/AChE |
| ML380 is a potent, subtype-selective, and brain-penetrant positive allosteric modulator (PAM) of M5 mAChR, with EC50s of 190 and 610 nM for human and rat M5, respectively. ML380 exhibits moderate selectivity versus the M1 and M3 mAChR subtypes. ML380 could increase the affinity of ACh for the M5 mAChR. | ||
| M29031 | ML418 | Potassium Channel |
| ML418 is a potent, selective and CNS penetrating Kir7.1 potassium channel blocker. ML418 inhibits Kir7.1 with an IC50 value of 0.31 μM. ML418 can be used for the research of neurological, cardiovascular, endocrine and muscle disorders. | ||
| M29857 | CAY10444 | LPL Receptor |
| BML-241 | ||
| CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca2+ in HeLa cells expressing S1P3 receptors. | ||
| M30210 | Verminoside | PARP |
| Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of PARP-1 and p53 proteins. | ||
| M30806 | MLS1082 | Dopamine Receptor |
| MLS1082 is a pyrimidone-based D1-like dopamine receptor positive allosteric modulator, with an EC50 of 123 nM for DA-stimulated G protein signaling. | ||
| M40720 | I-138 | Deubiquitinase |
| I-138 is an orally active, potent reversible inhibitor of USP1-UAF1, structurally related to ML323, showing synergistic binding to ubiquitin and mutually exclusive binding to ML323. I-138 induces mono-ubiquitination of FANCD2 and PCNA in MDA-MB-436 cells, increases PCNA and FANCD2 mono-ubiquitination in HAP-1 USP1 WT cells, and abrogates USP1 auto-cleavage in cells. | ||
| M49367 | SML-8-73-1 | Ras |
| SML-8-73-1 is a GDP analog and also a KRAS inhibitor that irreversibly covalently binds to the GTPase active site of KRAS, and its binding rate to KRAS G12C was more than 95% in a 1 mmol/L GDP/GTP environment, and the IC 50 value for the inhibition of the proliferation of lung cancer cells H358 was 26.6 μmol/L . | ||
| M49658 | ML115 | STAT |
| ML115 is a molecular probe of the signal transducer and activator of transcription (STAT3). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
